The most significant epidemiological trend sustaining the US Liver Biopsy Market is the surging prevalence of Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Non-Alcoholic Steatohepatitis (NASH), which affects tens of millions of Americans.
MASH, a severe form of fatty liver disease linked to the obesity and diabetes epidemics, necessitates accurate staging to guide...